Cardiovascular Imaging in the Era of Molecular Medicine

Editorial Staff | November 05, 2012 | Health Imaging | Molecular Imaging

Nov. 27, 8:30-10:00 a.m. | S504CD

This session focuses on the clinical role that molecular imaging could play in the management of cardiovascular disease. Molecular imaging application in atherosclerosis, myocardial infarction, thrombosis syndromes and cardiac transplant rejection are discussed, followed by a panel discussion on the future of the technology.

Speaker Information:

• Zahi Adel Fayad, PhD, Mount Sinai Hospital, New York City

• Farouc Amin Jaffer, MD, PhD, Harvard University, Boston

• Dara L. Kraitchman, DVM, PhD, Johns Hopkins University, Baltimore

• Patricia K. Nguyen, MD, Stanford University, Stanford, Calif.

Editorial Staff

Around the web

Radiology Business

Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business

‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.

Cardiovascular Business

Continuation of 99mTc-PYP shortage prompts need for alternative cardiac amyloidosis imaging

After three years of intermittent shortages of nuclear imaging tracer technetium-99m pyrophosphate, there are no signs of the shortage abating.

Cardiovascular Imaging in the Era of Molecular Medicine

Related Content

Around the web